Ideaya Biosciences Inc (IDYA)

NASDAQ
22.97
+0.13(+0.57%)
  • Volume:
    783,743
  • Bid/Ask:
    22.68/23.14
  • Day's Range:
    21.43 - 26.00

IDYA Overview

Prev. Close
22.84
Day's Range
21.43-26
Revenue
26.79M
Open
22.8
52 wk Range
10.9-26
EPS
-1.22
Volume
783,743
Market Cap
876.17M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
218,302
P/E Ratio
-
Beta
-
1-Year Change
91.93%
Shares Outstanding
38,293,974
Next Earnings Date
Nov 18, 2021
What is your sentiment on Ideaya Biosciences Inc?
or
Vote to see community's results!

Ideaya Biosciences Inc News

Ideaya Biosciences Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellBuyStrong BuyStrong Buy
Technical IndicatorsStrong SellStrong SellBuyStrong BuyStrong Buy
SummaryStrong SellStrong SellBuyStrong BuyStrong Buy

Ideaya Biosciences Inc Company Profile

Ideaya Biosciences Inc Company Profile

Employees
69

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company’s product candidate is IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting IDE397, a methionine adenosyltransferase 2a inhibitor for patients with solid tumors having MTAP deletions; PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in high microsatellite instability tumors. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Read More
  • probably not a good. The upward trend is already at its peak.
    0
    • its good time to invest. lol
      0
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.